Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium
Purpose: To evaluate the clinical outcome(s) and complication(s) of subconjunctival bevacizumab treatment in patients with recurrent pterygium. Methods: This prospective case series included patients who had undergone pterygium surgery and were diagnosed with recurrent pterygium. All patients received one subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL). The main outcome was the change in size and clinical appearance. The clinical appearance of the pterygium was graded according to Tan and colleagues. The horizontal size of the pterygium (from limbus to apex) was recorded from baseline to 2 months after injection. Treatment-related complications and adverse events were reported. Results: We included 36 eyes of 36 patients (18 males) with a mean age of 58.75 ± 10.98 years. Totally, 30.6% patients developed recurrent pterygium in both eyes (only the worst eye was treated), with 47.2% developing it in the left eye and 22.2% in the right eye. More than half the patients (58.3%) had a family history of pterygium. There was a significant difference in the size of pterygium at different intervals (P<0.05). Approximately two-thirds (66.7%) of patients presented with hyposphagma on the 2nd day after subconjunctival application; this value decreased to 30.6% by day 7 and to 0% at 1 month. Most patients (69.4%) exhibited amelioration of irritative symptoms within 2 days, 88.9% after 7 days, and 97.2% after 1 month. Conclusions: Subconjunctival bevacizumab injection is useful for the management of patients with recurrent pterygium, with no significant local or systemic adverse effects.
Main Authors: | Stival,Larissa Rossana Souza, Lago,Anelise Medeiros, Figueiredo,Marisa Novaes Falleiro Chaves de, Bittar,Ricardo Henrique Goulart, Machado,Márcia Leite, Nassaralla Junior,João Jorge |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Conselho Brasileiro de Oftalmologia
2014
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000100004 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutical evaluation of bevacizumab application in relapsed pterygium
by: Abrahão,Mayara Martins, et al.
Published: (2017) -
The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
by: Barros,Luiz F.M., et al.
Published: (2007) -
Effects of topical and subconjunctival use of bevacizumab on corneal neovascularization in rabbits' eyes
by: Lopes,Gerson Jorge Aparecido, et al.
Published: (2017) -
Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization
by: Ozdemir,Ozdemir, et al.
Published: (2014) -
The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model
by: Mello,Glauco Reggiani, et al.
Published: (2011)